

# Agenda

## 1st Core Group Meeting

Lisbon 9 January 2019 from 9:00 to 17:00

1. Welcome to participants

2. Adoption of agenda

3. Reporting of coordination activities:

- Grant Agreement
- Financial Reporting
- Scientific/networking Reporting and Monitoring

----- Coffee break 10.30 -----

4. Presentation and discussion of the advances in the Action

- Objectives, deliverables, tasks and timeline
- Working Groups
- Other management roles/structures
  - STSMs rules, planning, application form, assessment, model final report
  - Training schools rules, planning, assessment, satisfaction
- Implementation of COST policies on the promotion of Inclusiveness and Excellence, gender balance and Early Career Investigators (ECI)
- Lecture: 12.30. DRUG-INDUCED LIVER INJURY – When to suspect? How to confirm? Prof. Raul Andrade. University of Malaga/UMA- Spain

----- Lunch break 13.00 -----

5. Action implementation planning

- Monitoring of the Objective Achievement Indicators for MoU Objectives
- Activity and budget planning (Work and Budget Plan preparation)

----- Coffee break 15.30 -----

- Dissemination strategy/ planning (Publications and outreach activities)
  - Webpage, social media, initiatives to spread information on the activities and increase visibility to broaden the network

- Monitoring & Assessment of the progress and allocation of funds of the Action
6. Any Other Business (AOB)
7. Closing

**TASKS AND DELIVERABLES 1ST GRANT PERIOD 1 NOV 2018 TO 30 APRIL 2019**

<b>TASKS</b>	<b>DELIVERABLES</b>
<b>WG 1 IN DEPTH PHENOTYPING DILI</b>	
<ul style="list-style-type: none"> <li>✓ Harmonize nomenclature, clinical measurements, definitions, classification and outcomes</li> <li>✓ Standardize forms for prospective multicentre data collection, established and possibly novel and improved causality assessment tools;</li> </ul>	<ul style="list-style-type: none"> <li>✓ Standardized approach to diagnosis and SOPs for data/samples collection</li> <li>✓ Coordination of the development of pre-funded database of DILI patients providing a framework for the access to patient cohorts from different EU countries</li> <li>✓ A workshop on DILI diagnosis, classification and management for developing improved skills in scientific and clinical questions related to DILI</li> <li>✓ Explore setup an EASL SIG Group. Possibility to meet at each EASL meeting</li> </ul>
<b>WG 2 DILI RISK STRATIFICATION</b>	
Systematically review (and develop if needed) techniques and tools to evaluate the risk of DILI, quantify the degree of injury and impairment of function, and model clinical outcomes	<ul style="list-style-type: none"> <li>✓ EU Framework translational research plan for biomarker development</li> </ul>
<b>WG 3 PRECLINICAL EVALUATION OF DILI</b>	
Review in vitro and in silico models of hepatotoxicity and critically appraise their strengths, limitations and applications in pre-clinical evaluation	<ul style="list-style-type: none"> <li>✓ Set up STSMs and research exchange programs for ECIs to enhance research skills &amp; techniques</li> </ul>
<b>WG 4 CLINICAL TRIALS</b>	

<p>Define threshold criteria for patient inclusion in special patient populations monitoring plans, stopping rules, safety signals and outcome parameters to optimally plan future clinical trials; Review and evaluate therapeutic options for patients with DILI</p>	<ul style="list-style-type: none"> <li>✓ Set up STSMs and exchange programs for ECIs with the Regulatory Agencies</li> </ul>
<p><b>WG 5 KNOWLEDGE DISSEMINATION</b></p>	
<p>Coordinate the set-up and maintenance of the Website and social networks promotion of the Action and maintain updated information on recent activities and downloadable resources;</p>	<ul style="list-style-type: none"> <li>✓ Website setup, social media &amp; updates</li> <li>✓ Quality plan and good practice policies</li> <li>✓ Meeting with IAIH Group or Societies oncology or those that use immune check points inhibitors</li> </ul>

